Article
Immunology
Zesheng Peng, Jiajing Wang, Shiao Tong, Yuxi Wu, Dongye Yi, Wei Xiang
Summary: PDCL3 is an oncogene that is upregulated in multiple cancers and serves as a potential prognostic biomarker in glioma. Its expression is associated with epigenetic modifications and genetic mutations, and it may regulate cellular malignancy, cell communication, and extracellular matrix by interacting with the TCP1 complex. PDCL3 is also involved in the modulation of the glioma immune landscape, and its interference can inhibit the proliferation, invasion, and migration of glioma cells.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Genetics & Heredity
Yunyang Zhu, Songwei Feng, Zhaoming Song, Zhong Wang, Gang Chen
Summary: This study used bioinformatics methods to identify four immunotypes of lower-grade glioma (LGG) and found correlations between these immunotypes and clinical and immunogenomic factors. The study also revealed that LGGs in one immunotype were sensitive to certain drugs and immune checkpoint inhibitors, and were affected by specific pathways.
FRONTIERS IN GENETICS
(2022)
Review
Biochemistry & Molecular Biology
Yang Hu, Zhixing Li, Yichi Zhang, Yuzheng Wu, Zihao Liu, Jianhao Zeng, Zhexue Hao, Jin Li, Jiaoyan Ren, Maojin Yao
Summary: This review discusses the paradoxical roles of the tumor microenvironment (TME) in gliomas and provides an overview of recent advances in mouse models for studying the TME. Additionally, it summarizes the recent progress made in TME-targeting therapeutic strategies.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2023)
Article
Chemistry, Multidisciplinary
Chunrong Yang, Yujie Li, Yuchen Yang, Qiankun Ni, Zeyu Zhang, Yi Chai, Jinghong Li
Summary: This study demonstrates the potential of enhancing the efficacy of immunotherapy for glioma by targeting and modulating the tumor microenvironment. The researchers designed a nanomedicine that silenced SOCS1 and triggered a strong antitumor immune response, inhibiting tumor growth.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
(2023)
Review
Oncology
Moloud Sooreshjani, Shashwat Tripathi, Corey Dussold, Hinda Najem, John de Groot, Rimas V. Lukas, Amy B. Heimberger
Summary: Glioblastoma, a highly infiltrative tumor, often recurs despite multi-modal treatment. Novel strategies incorporating cytokines as potential therapeutic options, including virotherapy, systemic cytokine therapy, and cellular and gene therapy, are being explored to improve treatment outcomes in glioblastoma patients.
Review
Immunology
Stefan Forster, Ramin Radpour, Adrian F. Ochsenbein
Summary: Multiple myeloma (MM) is a hematologic malignancy characterized by the proliferation of clonal plasma cells in the bone marrow. The interaction between myeloma cells and the tumor microenvironment (TME) plays a crucial role in MM progression. Understanding the molecular mechanisms that drive MM and therapy resistance is essential for developing successful therapies and preventing MM recurrence. This review summarizes key mechanisms and emerging therapies in MM, including autocrine signaling, interactions with TME, and drug-resistance mechanisms.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Susan Brandenburg, Anne Blank, Alexander D. Bungert, Peter Vajkoczy
Summary: This article summarizes current research on methods to differentiate brain resident microglia from tumor-infiltrated macrophages, as well as their proportions and functional activities in glioma tissues.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Chemistry, Multidisciplinary
Tao Wang, Yunxia Zhou, Yunping Fan, Hao Duan, Xiaoyu Guo, Jinlong Chang, Youheng Jiang, Changxue Li, Zhang Fu, Yunfei Gao, Xiaoran Guo, Kastytis Sidlauskas, Zhenqiang He, Clive Da Costa, Xia Sheng, Dinglan Wu, Jinqiu Yuan, Huiliang Li, Yulong He, Yonggao Mou, Ningning Li
Summary: This study demonstrates that IDH mutation induces metabolic reprogramming in gliomas and influences the phenotypes of glioma-associated microglia/macrophages (GAMs). Gliomas expressing mutant IDH promote M1-like polarization of GAMs, while typical IDH induces M2-like polarization. Furthermore, the study reveals the involvement of the PERK/miR-19a/LDLR signaling pathway in regulating gliomal cholesterol transport and GAM phenotypes, suggesting it as a potential target pathway for glioma therapy.
Review
Oncology
Alexander Yuile, Joe Q. Wei, Aditya A. Mohan, Kelly M. Hotchkiss, Mustafa Khasraw
Summary: Gliomas are common and deadly brain tumors with limited treatment options. The complex interaction between glioma cells and non-cancerous cells in the brain tissue, as well as variations depending on specific mutations, play a crucial role in glioma development. Understanding these interactions and mutations is essential for identifying future treatments for gliomas.
Article
Immunology
Yuan Jiang, Qiankun Ji, Xiaoyan Long, Peng Wang, Zewei Tu, Xian Zhang, Xingen Zhu, Kai Huang, Jingying Li
Summary: The expression level of CLCF1 is related to the prognosis of glioma and is associated with the response to immunotherapy, suggesting that it may be a promising therapeutic target.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Biochemical Research Methods
Peng Zhang, Mingyue Liu, Ya Cui, Pan Zheng, Yang Liu
Summary: This study found that MSI-H and non-MSI-H samples exhibited clinical response and immune phenotypic differences in different cancer types. However, regardless of cancer types, the abundance of tumor-infiltrating immune cells was more strongly associated with clinical outcomes.
BRIEFINGS IN BIOINFORMATICS
(2021)
Review
Immunology
Yang Xu, Huikai Zhang, Qian Sun, Rongxin Geng, Fanen Yuan, Baohui Liu, Qianxue Chen
Summary: Gliomas, the most common primary malignant tumor in adults' central nervous system, still lack breakthroughs in long-term treatment. Abnormalities in the immune regulatory mechanism in the tumor microenvironment are crucial for tumor cell survival, with alterations in amino acid metabolism impacting tumor cells and immune regulation mechanisms. Studying immune regulation of tryptophan metabolism in the tumor microenvironment of gliomas can help identify potential targets for treatment and enhance the efficacy of immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Immunology
Dongming Yan, Weicheng Li, Qibing Liu, Kun Yang
Summary: The tumor immune microenvironment and immunotherapy in IDH-mutant gliomas have been extensively studied. IDH mutations inhibit immune evasion and T-cell responses, making it a potential target for immunotherapy.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Jiakai Hou, Yunfei Wang, Leilei Shi, Yuan Chen, Chunyu Xu, Arash Saeedi, Ke Pan, Ritu Bohat, Nicholas A. Egan, Jodi A. McKenzie, Rina M. Mbofung, Leila J. Williams, Zhenhuang Yang, Ming Sun, Xiaofang Liang, Jordi Rodon Ahnert, Navin Varadarajan, Cassian Yee, Yiwen Chen, Patrick Hwu, Weiyi Peng
Summary: This study used genome-wide CRISPR immune screens to identify immunosuppressive mechanisms in non-responders to cancer immunotherapy and integrated the results with multi-omics clinical data to evaluate the role of tumor intrinsic factors in regulating two key steps of cancer immunotherapy. Two distinct types of immune resistance regulators were revealed, with PRMT1 and RIPK1 identified as potential therapeutic targets to improve the efficacy of immunotherapy. Targeting PRMT1 and RIPK1 sensitized tumors to T-cell killing and anti-PD-1/OX40 treatment, providing novel targets for rational immuno-oncology combinations.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Genetics & Heredity
Xiangpan Li, Kewei Xiong, Dong Bi, Chen Zhao
Summary: In this study, computational tools based on CRISPR/Cas9 were used to predict the clinical outcomes and biological characteristics of low-grade glioma (LGG). By implementing various algorithms and analyses, a novel CRISPR/Cas9 screening potential index (CCSPI) was developed, which showed promise in predicting LGG prognosis. The model also provided insights into the interaction between the central nervous system and immune system in different LGG subtypes.
FRONTIERS IN GENETICS
(2022)